These findings suggest that NKT cells with an active phenotype may display an important role following anti-PD1 therapies in patients with malignant melanomas, given their known antitumor properties, in which activation and frequency levels might be controlled by epigenetic changes regulating B2M, SPI1, and CD1D expression in anti-PD1 resistant tumors. This evidence concerns the gene CD1D and melanoma.